Psychedelic Therapy: Types, Benefits, and Potential Risks

What is psychedelic therapy?

Psychedelic therapy, or psychedelic-assisted therapy, is a psychiatric approach that integrates psychedelic drugs with psychotherapy to address mental health disorders. This method is gaining attention in psychedelic research, particularly for treating posttraumatic stress disorder (PTSD) (Morland &. Woolley, 2024), depression, and anxiety. Unlike traditional treatments like selective serotonin reuptake inhibitors (SSRIs), psychedelic therapy leverages substances such as psilocybin and lysergic acid diethylamide (LSD) under medical supervision (Raj et al., 2023) to induce altered states of consciousness that may enhance therapeutic outcomes.

One of the most studied forms is MDMA-assisted therapy, primarily used for PTSD symptoms (Riaz et al., 2023). In randomized controlled trials, MDMA-assisted psychotherapy has shown promising results in reducing trauma-related distress. The therapeutic potential of psychedelic medicine is supported by human hallucinogen research, suggesting long-term benefits in emotional processing and cognitive flexibility.

However, clinical trials remain essential to establish efficacy and safety, as these substances are not yet widely approved for clinical use (Maia et al., 2024). Compared to conventional methods, psychedelic-assisted therapy requires careful administration within structured therapeutic settings to minimize risks.

The Multidisciplinary Association for Psychedelic Studies (MAPS) has led research on its use in substance abuse treatment (Emerson et al., 2014). While early findings are positive, further trials are necessary to establish safety and effectiveness. Assisted therapy with psychedelics remains an evolving field requiring rigorous clinical validation.

While research continues to improve, psychedelic therapy is emerging as a potential alternative for individuals with mental health conditions who have not responded to standard treatments.

Purpose of psychedelic therapy

Psychedelic therapy is gaining recognition for its therapeutic efficacy in addressing various mental illnesses and emotional distress. According to Yao et. al. (2024), they suggest its potential in managing treatment-resistant depression, major depressive disorder, and alcohol use disorder within a controlled clinical setting.

Anxiety reduction

Studies on psilocybin-assisted psychotherapy show promising results in reducing anxiety, particularly in individuals with life-threatening diseases. Unlike conventional medications, psychedelic substances may provide long-lasting relief after a single session. Preliminary findings suggest that psychedelics promote emotional flexibility, helping patients manage distress more effectively.

Emotional processing

Psychedelics such as lysergic acid diethylamide (LSD) and psilocybin enhance emotional openness, making psychedelic-assisted psychotherapy beneficial for trauma recovery. This therapy can help patients process repressed emotions, allowing for deeper introspection.

Neuroplasticity

Psychedelics influence neuroplasticity, promoting new neural connections that may support mental resilience. According to Grieco et al. (2022), substances like LSD and psilocybin stimulate synaptic growth, potentially aiding in treating depression and treatment-resistant depression.

Spiritual exploration

Some individuals undergoing psychedelic-assisted psychotherapy report profound experiences of interconnectedness and meaning, contributing to overall well-being. These effects may be particularly beneficial for those struggling with existential distress.

Treating mental health conditions

Psychedelic therapy is being studied for its effectiveness in treating depression, major depressive disorder, substance abuse, and alcohol use disorder. Additionally, controlled administration under health care providers is crucial to monitoring physiological responses, such as blood pressure regulation, and ensuring safety and efficacy in therapeutic applications.

Types of psychedelic therapy treatments

Psychedelic therapy involves various controlled substances used in clinical settings to treat substance use disorders, chronic stress, psychotic disorders, and eating disorders. Each treatment produces unique psychedelic experiences that impact cognition, emotions, and neuroplasticity.

Psilocybin treatment

Psilocybin treatment, derived from "magic mushrooms," is studied for its potential to treat depression and substance use disorders (Ziff et al., 2022). Clinical trials comparing psilocybin to a placebo group have shown significant symptom reduction in major depressive disorder.

Ayahuasca

Ayahuasca, a plant-based psychedelic brew from the Amazon, contains DMT, which induces intense psychedelic experiences (Ruffell et al., 2023). Studies suggest that Ayahuasca may help in substance abuse treatment, promoting emotional processing and self-reflection. Early findings indicate potential benefits in drug abuse recovery, particularly in reducing cravings and enhancing psychological insight when administered under medical supervision.

Lysergic acid diethylamide (LSD)

Lysergic acid diethylamide (LSD) is a powerful psychedelic known for altering perception and cognition (Stork & Henriksen, 2014). Research in human psychopharmacology suggests LSD enhances emotional resilience and introspection, which may be beneficial in managing chronic stress and psychotic disorders (Liechti, 2017). Its therapeutic value is being explored for treatment-resistant depression, with some studies showing potential long-term relief from symptoms.

Psilocin

Psilocin, the active metabolite of psilocybin, directly interacts with serotonin receptors, producing rapid therapeutic effects (Wulff et al., 2023). It is studied in psilocybin treatment trials for depression and anxiety. Unlike psilocybin, which requires metabolic conversion, psilocin acts immediately, potentially offering a faster onset of benefits for individuals with severe PTSD and mental illness.

Mescaline (peyote)

Mescaline, found in peyote and San Pedro cacti, has been traditionally used for spiritual and healing purposes. In modern clinical settings, mescaline is being researched for its role in treating substance use disorders and depression. Early studies suggest it may contribute to increased emotional awareness and cognitive flexibility, making it a candidate for psychedelic-assisted psychotherapy.

DMT

DMT (N, N-Dimethyltryptamine) is a short-acting psychedelic known for its intense psychedelic experiences (Alcohol and Drug Foundation, 2023). Some studies explore its potential role in addressing drug abuse and addiction when used in a controlled clinical setting with psychological support.

5-MeO-DMT

5-MeO-DMT, found in certain toad secretions and synthetic formulations, is a potent psychedelic with rapid and profound effects (Calina et al., 2021). Placebo group comparisons in early trials show promising results, though more studies are needed to confirm its safety and clinical outcomes.

Ibogaine

Ibogaine, derived from the African iboga plant, is being researched for its role in treating substance abuse and alcohol use disorder (Brown, 2013). Studies suggest that ibogaine may interrupt addictive patterns by resetting neural pathways associated with drug abuse.

MDMA

MDMA, commonly known as ecstasy, is primarily studied for MDMA-assisted psychotherapy in severe PTSD cases (Riaz et al., 2023). Unlike classical psychedelics, MDMA enhances emotional connectivity and reduces fear responses, improving the effectiveness of psychedelic-assisted psychotherapy.

Potential benefits of psychedelic therapy

Psychedelic therapy is being studied for its therapeutic purposes, particularly in addressing PTSD diagnosis, obsessive-compulsive disorder, and depression.

Unlike traditional treatments, it often delivers rapid and long-lasting results, with research showing sustained psychological effects even after a single session. This is especially beneficial for individuals with advanced-stage cancer, helping alleviate existential distress and improve emotional resilience. Additionally, classic hallucinogens facilitate deep emotional exploration by suppressing the brain’s default mode network, allowing patients to process trauma and anxiety in a controlled environment.

For those with PTSD diagnosis, this approach aids in confronting distressing memories in a structured way. Psychedelics also enhance neuroplasticity, promoting new neural connections that contribute to long-term mental health improvements. This effect is particularly relevant for individuals with obsessive-compulsive disorder and trauma-related conditions, where rigid thought patterns may be disrupted.

Main takeaways

Psychedelic therapy is emerging as a promising approach for therapeutic purposes, offering potential benefits for individuals with PTSD diagnosis, obsessive-compulsive disorder, substance use disorders, and advanced-stage cancer.

While classic hallucinogens show potential in creating new neural connections and promoting neuroplasticity, their use requires careful oversight in clinical settings. Ongoing research and human psychopharmacology studies continue to assess these treatments' risks and therapeutic value. As scientific understanding evolves, psychedelic therapy may become a transformative tool in modern mental health care under appropriate medical supervision.

References

Alcohol and Drug Foundation. (2023, August 24). DMT - Alcohol and Drug Foundation. https://adf.org.au/drug-facts/dmt/

Ayyub, J., Nandennagari, S., Edelbaum, D., Agbo, J., Nagendran, D., & Tamayo, L. (2023). Hallucinogen-induced persisting perception disorder: A case report. Cureus, 15(10), Article e46262. https://doi.org/10.7759/cureus.46262

Brown, T. (2013). Ibogaine in the treatment of substance dependence. Current Drug Abuse Reviews, 6(1), 3–16. https://doi.org/10.2174/15672050113109990001

Calina, D., Carvalho, F., & Docea, A. O. (2021). Toxicity of psychedelic drugs. In Elsevier eBooks (pp. 545–556). https://doi.org/10.1016/b978-0-323-85215-9.00022-2

Emerson, A., Ponté, L., Jerome, L., & Doblin, R. (2014). History and future of the Multidisciplinary Association for Psychedelic Studies (MAPS). Journal of Psychoactive Drugs, 46(1), 27–36. https://doi.org/10.1080/02791072.2014.877321

Grieco, S. F., Castrén, E., Knudsen, G. M., Kwan, A. C., Olson, D. E., Zuo, Y., Holmes, T. C., & Xu, X. (2022). Psychedelics and neural plasticity: Therapeutic implications. The Journal of Neuroscience, 42(45), 8439–8449. https://doi.org/10.1523/jneurosci.1121-22.2022

Liechti, M. E. (2017). Modern clinical research on LSD. Neuropsychopharmacology, 42(11), 2114–2127. https://doi.org/10.1038/npp.2017.86

Maia, J. M., de Oliveira, B. S. A., Branco, L. G. S., & Soriano, R. N. (2024). Therapeutic potential of psychedelics: History, advancements, and unexplored frontiers. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 131, Article 110951. https://doi.org/10.1016/j.pnpbp.2024.110951

Morland, L., & Woolley, J. (2024, August 27). Psychedelic-assisted therapy for PTSD. U.S. Department of Veterans Affairs. https://www.ptsd.va.gov/professional/treat/txessentials/psychedelics_assisted_therapy.asp

Raj, P., Rauniyar, S., & Sapkale, B. (2023). Psychedelic drugs or hallucinogens: Exploring their medicinal potential. Cureus, 15(11), Article e48719. https://doi.org/10.7759/cureus.48719

Riaz, K., Suneel, S., Hamza Bin Abdul Malik, M., Kashif, T., Ullah, I., Waris, A., Di Nicola, M., Mazza, M., Sani, G., Martinotti, G., & De Berardis, D. (2023). MDMA-based psychotherapy in treatment-resistant post-traumatic stress disorder (PTSD): A brief narrative overview of current evidence. Diseases, 11(4), Article 159. https://doi.org/10.3390/diseases11040159

Ruffell, S., Crosland‐Wood, M., Palmer, R., Netzband, N., Tsang, W., Weiss, B., Gandy, S., Cowley‐Court, T., Halman, A., McHerron, D., Jong, A., Kennedy, T., White, E., Perkins, D., Terhune, D. B., & Sarris, J. (2023). Ayahuasca: A review of historical, pharmacological, and therapeutic aspects. Psychiatry and Clinical Neurosciences Reports, 2(4). https://doi.org/10.1002/pcn5.146

Stork, C. M., & Henriksen, B. (2014). Lysergic acid diethylamide. In P. Wexler (Ed.), Encyclopedia of toxicology (3rd ed.). Academic Press. https://www.sciencedirect.com/science/article/abs/pii/B9780123864543007442

Wulff, A. B., Nichols, C. D., & Thompson, S. M. (2023). Preclinical perspectives on the mechanisms underlying the therapeutic actions of psilocybin in psychiatric disorders. Neuropharmacology, 231, Article 109504. https://doi.org/10.1016/j.neuropharm.2023.109504

Yao, Y., Guo, D., Lu, T.-S., Liu, F.-L., Huang, S.-H., Diao, M.-Q., Li, S.-X., Zhang, X.-J., Kosten, T. R., Shi, J., Bao, Y.-P., Lu, L., & Han, Y. (2024). Efficacy and safety of psychedelics for the treatment of mental disorders: A systematic review and meta-analysis. Psychiatry Research, 335, Article 115886. https://doi.org/10.1016/j.psychres.2024.115886

Ziff, S., Stern, B., Lewis, G., Majeed, M., & Gorantla, V. R. (2022). Analysis of psilocybin-assisted therapy in medicine: A narrative review. Cureus, 14(2), Article e21944. https://doi.org/10.7759/cureus.21944